PHP
ALNY icon

Parkman Healthcare Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Parkman Healthcare Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3M Buy
50,672
+23,756
+88% +$7.17M 1.56% 25
2026
Q1 		$8.91M Sell
26,916
-20,787
-44% -$7.07M 0.92% 40
2025
Q4 		$19M Sell
47,703
-39,987
-46% -$17.7M 1.81% 19
2025
Q3 		$40M Sell
87,690
-4,648
-5% -$1.89M 4.17% 3
2025
Q2 		$30.1M Buy
92,338
+23,400
+34% +$6.47M 3.46% 4
2025
Q1 		$18.6M Buy
68,938
+30,266
+78% +$7.78M 2.21% 14
2024
Q4 		$9.1M Buy
38,672
+13,187
+52% +$3.47M 1.21% 32
2024
Q3 		$7.01M Buy
+25,485
New +$6.64M 0.89% 42
2022
Q4 		– Sell
-10,873
Closed -$2.18M – 82
2022
Q3 		$2.18M Sell
10,873
-9,861
-48% -$1.88M 0.62% 53
2022
Q2 		$3.02M Sell
20,734
-33,274
-62% -$4.72M 1.11% 32
2022
Q1 		$8.82M Sell
54,008
-3,674
-6% -$560K 2.58% 12
2021
Q4 		$9.78M Sell
57,682
-17,285
-23% -$3.21M 2.16% 17
2021
Q3 		$14.2M Hold
74,967
– – 3.58% 6
2021
Q2 		$12.7M Buy
74,967
+9,924
+15% +$1.45M 2.78% 10
2021
Q1 		$9.18M Buy
65,043
+28,882
+80% +$4.35M 2.13% 13
2020
Q4 		$4.7M Buy
36,161
+5,298
+17% +$707K 1.2% 32
2020
Q3 		$4.49M Sell
30,863
-5,000
-14% -$711K 1.19% 37
2020
Q2 		$5.31M Sell
35,863
-500
-1% -$67.4K 1.5% 29
2020
Q1 		$3.96M Buy
36,363
+1,363
+4% +$157K 1.83% 21
2019
Q4 		$4.03M Buy
+35,000
New +$3.49M 1.16% 30

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parkman Healthcare Partners's ALNY Position: Q2 2026 in Review

Parkman Healthcare Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 88% in Q2 2026, buying an estimated $7.17M and bringing the position to 50,672 shares worth $15.3M. The position accounts for 1.56% of the portfolio, ranked #25.

Parkman Healthcare Partners first reported a position in ALNY in Q4 2019 and has held it in 20 quarters since. The position peaked at $40M in Q3 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Parkman Healthcare Partners held 50,672 shares of Alnylam Pharmaceuticals worth $15.3M as of Q2 2026.
  • Parkman Healthcare Partners bought 23,756 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $7.17M.
  • Alnylam Pharmaceuticals made up 1.56% of Parkman Healthcare Partners's portfolio in Q2 2026, its #25 holding.
  • Parkman Healthcare Partners first reported a position in Alnylam Pharmaceuticals in Q4 2019 and has held it in 20 quarters since.
  • Parkman Healthcare Partners's Alnylam Pharmaceuticals position peaked at $40M in Q3 2025.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.